This article is more than 5 years old. Information may no longer be current.

Janssen, MeiraGTx to develop gene therapy programs

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Janssen Pharmaceutical Companies announced a worldwide collaboration and license agreement with MeiraGTx Holdings to develop, manufacture and commercialize gene therapy programs for inherited retinal diseases.

According to a Janssen press release, the companies also will explore new targets for inherited retinal diseases and further develop adeno-associated virus manufacturing technology.

The agreement will see Janssen and MeiraGTx develop Janssen’s clinical stage inherited retinal disease portfolio, including product candidates for achromatopsia and X-linked retinitis pigmentosa.

MeiraGTx will grant Janssen an exclusive worldwide license to clinical assets in MeiraGTx’s inherited retinal disease portfolio. Janssen will have an exclusive option to license new treatments for other inherited retinal diseases.

“Janssen is excited to expand our portfolio with the addition of innovative assets that have the potential to improve sight or prevent the progression to blindness in inherited retinal diseases which currently have no treatment options,” James List, MD, PhD, global therapeutic area head, cardiovascular and metabolism, Janssen Research and Development, said in the release.